MedMira Q3 FY26 net loss narrows to $483,660; revenue more than doubled to $241,189 from year-ago quarter

• MedMira posted Q3 FY2026 revenue of $241,189, more than doubled from $24,503 in Q2 FY2026.
• Net loss narrowed to $483,660 from $657,552 a year earlier.
• Operating expenses edged up to $441,218 from $423,180 in Q2 FY2026.
• Working capital deficit widened 2% to $365,147, while liabilities rose $306,725 versus Q2 FY2026.
• Advanced Health Canada review for Multiplo TP/nTP; completed phase two trials post-quarter, data to support the application.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MedMira Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202606292000ACCESSWRNAPR_____1184115) on June 30, 2026, and is solely responsible for the information contained therein.